Big dreams, big pay and a big IPO: Mod­er­na lights up a pitch for a record $500M biotech IPO

Mod­er­na’s ex­ec­u­tive team nev­er does any­thing small — or non-con­tro­ver­sial.

They’ve built a biotech uni­corn with a $7.5 bil­lion val­u­a­tion with­out any­thing close to piv­otal da­ta to back up their am­bi­tions in mes­sen­ger RNA. A le­gion of crit­ics, led by Stat News, has poked at their busi­ness mod­el and as­pi­ra­tions. And the ju­ry is still out on whether or not the mR­NA com­pa­nies that have at­tract­ed at­ten­tion in the field can do what they say they can do — at least in a rea­son­able time frame for com­mer­cial­iza­tion.

But CEO Stephane Ban­cel isn’t let­ting any of that get in the way of his plans to go pub­lic.

On Fri­day Mod­er­na filed plans for a record $500 mil­lion IPO, which would of­fer one of the best fund­ed biotechs in Boston an even deep­er pool of cash to draw on — if they’re suc­cess­ful. If they come even close, they’ll eclipse the record $372.6 mil­lion biotech IPO Arie Bellde­grun and David Chang com­plet­ed a few weeks ago for Al­lo­gene.

Right now, the big mon­ey is flow­ing fast in the in­dus­try. And Mod­er­na isn’t wait­ing to see if the win­dow will close any­time soon.

The big idea at Mod­er­na is that they can use mR­NA to dis­patch the cod­ing nec­es­sary to turn cells in­to drug-mak­ing fac­to­ries — a killer ap­pli­ca­tion of tech that could rev­o­lu­tion­ize the way a broad range of dis­eases are treat­ed. But the mar­ket won’t give them an un­lim­it­ed amount of time to prove they can do this.

Mod­er­na has been lay­ing the foun­da­tion for this IPO since Flag­ship launched the com­pa­ny 6 years ago. And they are go­ing out be­hind a pro­fes­sion­al line­up of heavy­weight un­der­writ­ers — Mor­gan Stan­ley, Gold­man Sachs, JP­Mor­gan, Bo­fA Mer­rill Lynch, Bar­clays, Piper Jaf­fray, Bryan Gar­nier, Od­do, Op­pen­heimer, Need­ham and Chardan.

“We see mR­NA func­tion­ing as the ‘soft­ware of life.’ Every cell us­es mR­NA to pro­vide re­al time in­struc­tions to make the pro­teins nec­es­sary to dri­ve all as­pects of bi­ol­o­gy, in­clud­ing in hu­man health and dis­ease,” reads the S-1. “This was cod­i­fied as the cen­tral dog­ma of mol­e­c­u­lar bi­ol­o­gy over 50 years ago, and is ex­em­pli­fied in the schemat­ic be­low.”


It’s any­thing but cheap. Mod­er­na has burned through $865 mil­lion through the end of Sep­tem­ber. A chunk of that has gone to build­ing out man­u­fac­tur­ing as they build out the pipeline. And they don’t short­change their ex­ecs on pay. 

Ban­cel earned a $6.8 mil­lion pay pack­age for last year,  which is sig­nif­i­cant­ly less than the $24 mil­lion pack­et hand­ed to Pres­i­dent Stephen Hoge. Lorence Kim, the CFO, bagged $9.3 mil­lion. For a start­up biotech, those are ex­tra­or­di­nar­i­ly high amounts.

Mod­er­na didn’t quite fill in all the blanks for their S-1. The ros­ter of eq­ui­ty stakes held by the top share­hold­ers that must be at­tached to each fil­ing is left blank, pre­sum­ably to be filled in at a lat­er point. 

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Adeno-associated virus-1 illustration; the use of AAVs resurrected the gene therapy field, but companies are now testing the limits of a 20-year-old technology (File photo, Shutterstock)

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Nicole Paulk was scrolling through her phone in bed early one morning in June when an email from a colleague jolted her awake. It was an article: Two patients in an Audentes gene therapy trial had died, grinding the study to a halt.

Paulk, who runs a gene therapy lab at the University of California, San Francisco, had planned to spend the day listening to talks at the American Association for Cancer Research annual meeting, which was taking place that week. Instead, she skipped the conference, canceled every work call on her calendar and began phoning colleagues across academia and industry, trying to figure out what happened and why. All the while, a single name hung in the back of her head.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO take any board post in an industry where interests can simultaneously connect and collide on multiple levels of operations.

The tie set the stage for an important manufacturing connection. The Australian pharma giant agreed to supply the country with 10s of millions of AstraZeneca’s Covid-19 vaccine, once it passes regulatory muster.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Yanay Ofran (L) and Anat Binur (Ukko)

Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

Little capsules of peanut powder drove Nestlé’s $2.6 billion buyout of Aimmune. Now, with $40 million in new funding, a fledgling biotech is promising to bring a more sophisticated version of that protein therapy that can go much, much further.

Ukko’s goal is two-pronged — with the initial products spanning therapeutic and food — but it’s grounded in the same protein engineering platform, co-founder and CEO Anat Binur told Endpoints News.

As tar­get­ed ther­a­pies get ever more pre­cise, Deer­field un­veils $50M bet on an Har­vard pro­fes­sor's chem­istry in­sights

Behind the seemingly simple concept of targeted cancer therapies is the drug developer’s headache that the target is always changing. Each generation of kinase inhibitors may be ostensibly hitting the same oncogene, but in addition to blocking the wildtype oncogene, they must now also address the mutations that have developed along the way, spurring resistance to current drugs.

The more those target kinases evolve, too, the more they could resemble off-target kinases you don’t want to bind. So each iteration requires more selectivity — sometimes down to differences of a few atoms.

Vincent Sandanayaka (file photo)

UP­DAT­ED: Ex-MD An­der­son chief De­Pin­ho is help­ing launch an­oth­er biotech — and he's stick­ing with fa­mil­iar ground

Years after co-founding SINE-focused Karyopharm and stirring up controversy at MD Anderson, Ronald DePinho is helping uncloak a new biotech targeting solute carrier transporter proteins — and Karyopharm’s former head of chemistry is leading the charge.

Nirogy Therapeutics emerged from stealth mode on Tuesday with a $16.5 million Series A round and plans to hit the clinic by 2022. The financing should be enough to carry the startup’s lead program, a small molecule lactate transport inhibitor, through Phase I, CEO Vincent Sandanayaka said.

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.

The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.